Observational studyThe Indian journal of medical research2025
Natural history & quality of life in Glanzmann thrombasthenia & Bernard Soulier syndrome: An observational study from India.
Observational study in The Indian journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- [Hereditary disorders of hemostasis in obstetrics 1/2-Anesthesiological aspects of primary hemostasis].Die Anaesthesiologie · 2026Review
- Efficacy and safety of recombinant activated factor VII for secondary prophylaxis in patients with Glanzmann thrombasthenia.Research and practice in thrombosis and haemostasis · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & objectives Inherited platelet function disorders (IPFDs) are not well studied as compared to haemophilia and other bleeding disorders. Present study is aimed to understand the natural history and quality-of-life (QoL) in the two well studied IPFDs i.e. Glanzmann thrombasthenia (GT) and Bernard Soulier syndrome (BSS). Methods This is an ambispective, observational study. Demographics, medical data, mortality due to bleeding, comorbidities and treatment products were recorded. Health related quality of life (HRQoL) was captured using EuroQol five-dimensional questionnaire (EQ-5D), 36-Item short form health survey (SF-36) and functional assessment of chronic illness therapy (FACIT) scales. The severity of bleeding was assessed by annual bleed rate (ABR) and International Society on Thrombosis and Haemostasis - Bleeding assessment tool (ISTH-BAT) score. Results The median (interquartile range; IQR) age of 76 study participants (64 GT, 12 BSS) was 14 yr (9-19 yr). Epistaxis, ecchymosis, gingival bleed, gastrointestinal bleed, and soft tissue bleed were the commonest clinical manifestations. Menorrhagia was seen in all females in the reproductive age group. There was a statistically significant difference in the mean ISTH-BAT scores between GT and BSS (P=0.016). Platelet transfusion was the main mode of treatment; none of the patients in the present series were on activated recombinant factor VII (rFVIIa) therapy. Between 2000 and 2025, 13 deaths were reported (due to bleeding) mainly due to inaccessibility to treatment or treatment products. The relationship between quality of life (QoL) scores and ISTH-BAT score was weak. Interpretation & conclusions The need for optimal treatment strategies to improve QoL and providing timely access to specific treatment products to prevent mortality is underscored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.